Plant biopharming of monoclonal antibodies
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ko, K | - |
dc.contributor.author | Koprowski, H | - |
dc.date.accessioned | 2023-06-08T02:40:55Z | - |
dc.date.available | 2023-06-08T02:40:55Z | - |
dc.date.issued | 2005-07 | - |
dc.identifier.issn | 0168-1702 | - |
dc.identifier.issn | 1872-7492 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/66691 | - |
dc.description.abstract | Recent advances in molecular biology and plant biotechnology have shifted the concept of growing crops as a food source to serving as a bioreactor for the production of therapeutic recombinant proteins. Plants are potential biopharming factories because they are capable of producing unlimited numbers and amounts of recombinant proteins safely and inexpensively. In the last two decades, plant production systems have been developed for monoclonal antibody production, which has been useful in passive immunization of viral or bacterial diseases. Recently, a recombinant monoclonal antibody for rabies prophylaxis was produced in transgenic plants. Rabies virus epidemics remain still problematic throughout the world, and adequate treatment has been hampered by the worldwide shortage and high cost of prophylactic antibodies such as HR1G. Successful mass production of this monoclonal antibody in plants might help to overcome these problems. An effective plant production system for recombinant biologicals requires the appropriate heterologous plant expression system, the optimal combination of gene expression regulatory elements, control of post-translational processing of recombinant products, and efficient purification methods for product recovery. This review discusses recent biotechnology developments for plant-derived monoclonal antibodies and discusses these products as a promising approach to rabies prophylaxis and the consequence for global health benefits. (c) 2005 Published by Elsevier B.V. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER | - |
dc.title | Plant biopharming of monoclonal antibodies | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.virusres.2005.03.016 | - |
dc.identifier.bibliographicCitation | VIRUS RESEARCH, v.111, no.1, pp 93 - 100 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000229670900012 | - |
dc.identifier.scopusid | 2-s2.0-19444372752 | - |
dc.citation.endPage | 100 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 93 | - |
dc.citation.title | VIRUS RESEARCH | - |
dc.citation.volume | 111 | - |
dc.type.docType | Article; Proceedings Paper | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | rabies | - |
dc.subject.keywordAuthor | monoclonal antibody | - |
dc.subject.keywordAuthor | biopharming | - |
dc.subject.keywordAuthor | glycosylation | - |
dc.subject.keywordPlus | RECOMBINANT ANTIBODIES | - |
dc.subject.keywordPlus | PROTEIN GLYCOSYLATION | - |
dc.subject.keywordPlus | TRANSGENIC PLANTS | - |
dc.subject.keywordPlus | GENE-EXPRESSION | - |
dc.subject.keywordPlus | TOBACCO | - |
dc.subject.keywordPlus | ACCUMULATION | - |
dc.subject.keywordPlus | CELL | - |
dc.subject.keywordPlus | IMMUNOMODULATION | - |
dc.subject.keywordPlus | RHIZOSECRETION | - |
dc.subject.keywordPlus | TRANSFORMATION | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.